N = 29 | |||
---|---|---|---|
Age (years) | Mean | 64 | |
Median (range) | 65 | (39–81) | |
Gender n (%) | Male | 19 | (65.5) |
Female | 10 | (34.5) | |
Performance status n (%) | 0 | 13 | (44.8) |
1 | 16 | (55.2) | |
Histologic subtype n (%) | Adenocarcinoma | 9 | (31.0) |
Squamous cell | 17 | (58.6) | |
Neuro-endocrine | 3 | (10.4) | |
Stage n (%) | II | 4 | (13.8) |
III | 21 | (72.4) | |
IV | 4 | (13.8) | |
Chemotherapy n (%) | Platinum doublet | 26 | (89.6) |
Monotherapy | 3 | (10.4) | |
Radiation dose (gray) | Mean | 61.6 | |
Median (range) | 66 | (37–70) |